dsipar DREAM SPRAY DSIP | Neuropeptide Lab Research

As MOTS-c activates AMPK and NRF2, it also indirectly suppresses the mTOR (mechanistic target of rapamycin) pathway, the master growth and anabolism regulator that, when chronically overactivated, accelerates the accumulation of senescent cells

As of right now, the benefits are unsubstantiated

RAD-140 and Ostarine are not approved for human use outside research

Clinical trials combining these agents reported 35-40% discontinuation rates when both were dosed together

FDA to Revisit BPC-157 and Other Peptides On July 2324, 2026, FDA's Pharmacy Compounding Advisory Committee will consider whether BPC-157, along with KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide, should be included on the Section 503A Bulks List for pharmacy compounding

Store lyophilized vials at -20C, protected from light